Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study
The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study will impact testing going forward.
Updated results from the KEYNOTE-799 study, presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) Singapore, revealed pembrolizumab (Keytruda) plus concurrent chemoradiation therapy may be effective for treating patients with unresectable, locally advanced, stage III non–small cell lung cancer (NSCLC).
In an interview with CancerNetwork®, Salma Jabbour, MD, chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey, explained how the results of the ongoing study may guide testing moving forward.
Transcription:
The results of this study will hopefully help to guide phase 3 testing, which is currently ongoing in KEYLYNK-012 (NCT04380636). [This study] will look at the earlier incorporation of pembrolizumab with concurrent chemo-radiotherapy and will compare it to the standard of care, which is to receive immunotherapy after the completion of chemo-radiotherapy for stage III non–small cell lung cancer. It will be very exciting to see what these results will be and how they may change or improve our practice going forward to help patients.
